Respira Therapeutics, Inc.
http://www.respiratherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Respira Therapeutics, Inc.
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.
Venture Funding Deals: Cell Medica Raises $73.2m, Tango Dances In With $55m
Novel approaches to infectious diseases and cancer garnered significant VC cash in recent months, including monoclonal antibodies to treat and prevent S. aureus, Cell Medica's next-generation T cell therapies and Tango's platform focused on genetic drivers of cancer.
Deals Shaping The Medical Industry, May 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice